Currently, there are 48.64M common shares owned by the public and among those 48.20M shares have been available to trade.
The company’s stock has a 5-day price change of 3.03% and -46.13% over the past three months. CUE shares are trading -71.02% year to date (YTD), with the 12-month market performance down to -80.08% lower. It has a 12-month low price of $0.62 and touched a high of $3.90 over the same period. CUE has an average intraday trading volume of 399.49K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -11.56%, -39.99%, and -61.73% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Cue Biopharma Inc (NASDAQ: CUE) shares accounts for 35.92% of the company’s 48.64M shares outstanding.
It has a market capitalization of $37.21M and a beta (3y monthly) value of 1.98. The earnings-per-share (ttm) stands at -$1.07. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.24% over the week and 12.80% over the month.
Earnings per share for the fiscal year are expected to increase by 17.12%, and 28.70% over the next financial year.
Looking at the support for the CUE, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on March 13, 2024, with the firm’s price target at $6. Oppenheimer coverage for the Cue Biopharma Inc (CUE) stock in a research note released on June 26, 2023 offered a Outperform rating with a price target of $10. Piper Sandler was of a view on November 21, 2022 that the stock is Overweight, while H.C. Wainwright gave the stock Buy rating on January 13, 2022, issuing a price target of $20. Craig Hallum on their part issued Buy rating on January 03, 2022.
